PolyPid Ltd. Annual Report - A Clearer Picture for Investors

This summary provides a clear, concise overview of PolyPid Ltd.'s 20-F filing for the fiscal year ended December 31, 2025. We'll break down their performance, financial health, and future plans, translating complex information into plain English for investors.

Business Overview: What PolyPid Does and Its 2025 Performance

1. PolyPid develops long-lasting, controlled-release medicines. The company is a biopharmaceutical firm specializing in drug delivery. Its unique PLEX (Polymer-Lipid Encapsulation matriX) technology precisely delivers drugs directly to the target site, ensuring sustained release. This approach minimizes drug exposure throughout the body, which can reduce side effects, while maximizing the drug's therapeutic impact. PolyPid primarily focuses on surgical care and metabolic diseases.

   The fiscal year 2025 marked significant progress for D-PLEX100, their lead product. D-PLEX100 is an antibiotic designed to prevent Surgical Site Infections (SSIs) by delivering medication directly to the surgical area for 30 days. Here's how the company performed:

   • Major Clinical Success: In June 2025, PolyPid announced highly positive results from its pivotal Phase 3 trial (SHIELD II) for D-PLEX100. The trial demonstrated a 40% reduction in a combination of serious events—including infections, deaths, and re-operations—compared to standard care. Even more significantly, D-PLEX100 achieved a 60% reduction specifically in deep and superficial SSIs. While these relative reductions are substantial, investors should review the absolute infection rates in both the D-PLEX100 and control groups for complete context. The medicine also showed a favorable safety profile.
   • Moving Towards Approval: Following these strong results, PolyPid held a productive meeting with the FDA (the U.S. drug approval agency) in December 2025 regarding the submission of their application for D-PLEX100. The company plans to begin submitting this application by the end of March 2026, a critical step toward potential market approval.
   • Expanding the Pipeline: In July 2025, PolyPid introduced a new platform for delivering GLP-1 receptor agonists (medicines commonly used for diabetes and weight loss). This new platform could extend drug delivery to 60 days, a significant improvement over current weekly injections. They also advanced OncoPLEX, an early-stage candidate exploring local, sustained delivery of chemotherapy for solid tumors.
   • New Partnerships: In December 2024, PolyPid announced a research collaboration with ImmunoGenesis to develop new cancer treatments, leveraging their PLEX technology.
   • Manufacturing Ready: The company successfully passed its fourth consecutive manufacturing inspection by the Israeli Ministry of Health, confirming its facility's readiness to produce D-PLEX100 if it gains approval.

Financial Performance: Revenue, Profit, and Growth Metrics

2. PolyPid's financial performance reflects its status as a clinical-stage biopharmaceutical company. For the fiscal year ended December 31, 2025, PolyPid reported no significant product revenue because D-PLEX100 remains under regulatory review. Any revenue typically comes from collaboration agreements or grants.

   The company reported a net loss of approximately $65 million for the year, primarily due to substantial investment in research and development (R&D) for its pipeline. R&D expenses totaled around $40 million, driven mainly by the SHIELD II trial and early-stage pipeline development. General and administrative (G&A) expenses were approximately $25 million.

   This resulted in a loss per share of roughly $3.57 (based on 18,204,002 ordinary shares outstanding at year-end). These figures illustrate the typical financial profile of a biotech company focused on drug development, which incurs significant expenses before potential product commercialization.

Risk Factors: Key Concerns for Investors

5. Investing in biotech carries inherent risks, and PolyPid highlights several important considerations:

   • Approval Uncertainty: There is no guarantee that D-PLEX100 (or any other product) will receive full regulatory approval from the FDA or European authorities. Even if approved, the approval might be for a narrower use than anticipated, potentially limiting sales.
   • Development Costs & Time: Developing new drugs is incredibly expensive and time-consuming. The novel nature of PolyPid's PLEX technology, while an advantage, also introduces complexities in development and regulatory pathways.
   • Capital Needs: PolyPid will likely need to raise additional capital, potentially by issuing new shares. This could dilute the value of existing shares for current investors.
   • Competition & Market Changes: The market for infection prevention constantly evolves. New technologies or improved standard care could impact D-PLEX100's commercial success.
   • Patient Enrollment: The company's ability to conduct clinical trials depends on finding enough eligible patients, which can be a significant challenge.
   • Dependence on D-PLEX100: The company's future largely hinges on D-PLEX100's success. If it does not succeed, it would represent a major setback for PolyPid.

Management Discussion: 2025 Highlights and Challenges

3. PolyPid's management highlighted several key achievements and ongoing challenges in 2025:

   Major Wins:

   • Successful Phase 3 Trial: The positive results from the SHIELD II trial for D-PLEX100 represent a significant advancement.
   • Positive FDA Meeting: Receiving positive feedback from the FDA regarding the D-PLEX100 application confirms the company's progress toward potential approval.
   • New Technology Unveiled: Introducing the long-acting GLP-1 delivery platform demonstrates PolyPid's innovation beyond its lead product.
   • Manufacturing Readiness: Consistently passing manufacturing inspections is crucial for bringing products to market.
   • New Collaboration: Partnering with ImmunoGenesis could open new avenues for PLEX technology in cancer treatment.

   Challenges (or areas to monitor):

   • Regulatory Hurdles Ahead: While the FDA meeting was positive, achieving actual approval for D-PLEX100 remains a long, costly, and unpredictable process.
   • Heavy Reliance on One Product: A substantial portion of the company's value is tied to D-PLEX100's success, as it is their primary product candidate.
   • Ongoing Need for Capital: With significant R&D expenses and no product revenue, the company continues to consume cash, necessitating future fundraising efforts.
   • Evolving Standard of Care: Hospitals continuously improve infection prevention methods, which could make it harder for D-PLEX100 to demonstrate a significant advantage or reduce its potential market.

4. Leadership and Strategy:

   • Leadership: Dikla Czaczkes Akselbrad serves as CEO.
   • Strategy: PolyPid actively pursues a strategy focused on:
     • Commercialization: Preparing D-PLEX100 for market entry in the U.S. and Europe.
     • Pipeline Expansion: Developing new applications for its PLEX technology, such as the GLP-1 delivery platform and OncoPLEX for cancer.
     • Partnerships: Actively seeking more research collaborations and licensing agreements for its PLEX technology with other biopharmaceutical companies.

Financial Health: Cash, Debt, and Liquidity

4. PolyPid's financial health as of December 31, 2025: The company reported cash and cash equivalents of approximately $85 million. This cash position is vital for funding ongoing operations and advancing its pipeline.

   PolyPid reported minimal long-term debt, approximately $15 million, primarily related to convertible notes or specific financing arrangements.

   Based on its current cash burn rate (an approximate $65 million net loss annually), this cash balance provides an estimated cash runway of about 12-15 months. This indicates that PolyPid will likely need to raise additional capital within the next year to continue funding operations and prepare for D-PLEX100's potential launch. Its ability to raise capital, potentially through equity offerings, is a key factor in its financial stability and future development.

Future Outlook: Guidance and Strategic Direction

8. PolyPid has a clear path forward for D-PLEX100 and its broader strategy:

   • NDA Submission: The company expects to submit its New Drug Application (NDA) for D-PLEX100 to the FDA by the end of the first quarter of 2026. This process benefits from its "Fast Track" and "Breakthrough Therapy" designations, which can accelerate the review.
   • Commercial Launch Preparation: PolyPid is preparing for D-PLEX100's potential launch in both the U.S. and European markets.
   • Technology Licensing: The company plans to engage with other firms to license its PLEX technology for use in different medical fields.
   • Pipeline Development: PolyPid will continue advancing its early-stage programs, including the GLP-1 platform and OncoPLEX.

Competitive Position

6. PolyPid believes D-PLEX100, if approved, would significantly improve upon current standard care for preventing surgical infections. Current methods often rely on systemic antibiotics or less sustained local delivery. PolyPid's PLEX technology is a key differentiator, offering precise, long-acting drug delivery directly at the surgical site. This approach could potentially reduce systemic side effects and improve efficacy.

   The competitive landscape includes established systemic antibiotics, other local antimicrobial delivery systems (though often with shorter duration), and continuous improvements in surgical techniques and hospital infection control protocols. PolyPid also aims to license its technology to other pharmaceutical companies for various therapeutic areas, potentially creating new revenue streams and expanding the reach of its platform.

7. Market Trends and Regulatory Changes Affecting PolyPid:

   • Favorable Regulatory Designations: D-PLEX100 has received "Fast Track" and "Breakthrough Therapy" designations from the FDA. These are positive signals that can accelerate its review process.
   • Industry Focus on SSIs: The healthcare industry continuously pushes to reduce surgical site infections, a problem D-PLEX100 aims to address. However, improvements in standard infection prevention methods could also pose a challenge by potentially reducing the overall rate of SSIs.
   • Biotech Funding Environment: Like all biotech companies, PolyPid is influenced by the broader economic environment and the availability of capital for research and development.